(Image Source: fitsugar)

 

BY EMILY ALLEN

 

Should it stay or should it go? An FDA advisory panel shot down the diet pill Qnexa back in 2010.  But a new panel weighed in, and gave it a thumbs-up Wednesday. HLN thinks this could be a big step toward getting smaller.

“The FDA may approve a weight loss drug for the first time in 10 years.  And advisory panel is recommending approval of Qnexa, the prescription drug cuts your appetite.  People that tried it lost about 10 percent of their body weight.”

And according to CNBC, this new drug sure is getting a lot of attention.

“Nothing gets the general news media in a tizzy like a new diet drug.”

“Because this is the type of thing that everyone would want it and go after it.”

But the LA Times reports this drug might not be easy to get.  The panel recommended there be measures in place so people can’t use the drug as a quick fix.

“Qnexa users would likely have to order the drug through mail-order pharmacies, a strategy to limit easy access, such as by online purchasing.”

Fox News explains users who do get their hands on the drug could see more changes to their health than just shedding a few pounds.  And the drug’s side effects are the reason the drug got a thumbs-down from the 2010 advisory panel.

“This time the paneling is asking the FDA to require the company to do some more research into the side effects. Those side effects could also include raised heart rate, psychiatric problems, and birth defects.”

But even with the panel’s approval — CNN’s Dr. Sanjay Gupta is still leery about Qnexa, even with the panel’s approval.

“But there’s a lot of caveats with this pill.  The thing about a lot of these diet pills in the past, including more than a decade ago, they’re on the market for a while, the side effects get more amplified, you see it in more people, and then they get taken off the market.”

TIME says the FDA usually follows recommendations from panels – but it doesn’t have to.  The FDA will make its final decision in April. (SOC)

Panel Gives Green Light to Prescription Weight Loss Pill

by
0
Transcript
Feb 24, 2012

Panel Gives Green Light to Prescription Weight Loss Pill

(Image Source: fitsugar)

 

BY EMILY ALLEN

 

Should it stay or should it go? An FDA advisory panel shot down the diet pill Qnexa back in 2010.  But a new panel weighed in, and gave it a thumbs-up Wednesday. HLN thinks this could be a big step toward getting smaller.

“The FDA may approve a weight loss drug for the first time in 10 years.  And advisory panel is recommending approval of Qnexa, the prescription drug cuts your appetite.  People that tried it lost about 10 percent of their body weight.”

And according to CNBC, this new drug sure is getting a lot of attention.

“Nothing gets the general news media in a tizzy like a new diet drug.”

“Because this is the type of thing that everyone would want it and go after it.”

But the LA Times reports this drug might not be easy to get.  The panel recommended there be measures in place so people can’t use the drug as a quick fix.

“Qnexa users would likely have to order the drug through mail-order pharmacies, a strategy to limit easy access, such as by online purchasing.”

Fox News explains users who do get their hands on the drug could see more changes to their health than just shedding a few pounds.  And the drug’s side effects are the reason the drug got a thumbs-down from the 2010 advisory panel.

“This time the paneling is asking the FDA to require the company to do some more research into the side effects. Those side effects could also include raised heart rate, psychiatric problems, and birth defects.”

But even with the panel’s approval — CNN’s Dr. Sanjay Gupta is still leery about Qnexa, even with the panel’s approval.

“But there’s a lot of caveats with this pill.  The thing about a lot of these diet pills in the past, including more than a decade ago, they’re on the market for a while, the side effects get more amplified, you see it in more people, and then they get taken off the market.”

TIME says the FDA usually follows recommendations from panels – but it doesn’t have to.  The FDA will make its final decision in April. (SOC)

View More
Comments
Newsy
www3